-
Judge in Johnson & Johnson Talc Case Allows Jurors to See Advertisements
Like many people diagnosed with asbestos-related diseases like mesothelioma and ovarian cancer, Bob Sugarman blames asbestos-contaminated talc in Johnson & Johnson’s Baby Powder for his wife Marilyn Seskin’s cancer death. His personal injury lawsuit against the consumer giant is currently being heard in a Miami, Florida courtroom, and yesterday Miami-Dade Circuit Judge William Thomas allowed
-
Florida Jury Hears Mesothelioma Claim Against Johnson & Johnson
Last week, a Florida jury began hearing details surrounding the death of a Florida anesthesiologist who succumbed to a rare cancer similar to malignant peritoneal mesothelioma. Bob Sugarman is suing Johnson & Johnson following the death of his wife, Marilyn Seskin. He is accusing the company of knowingly selling asbestos-contaminated baby powder.
-
Mesothelioma Physicians at Philadelphia’s Fox Chase Cancer Center Receive $1.2 Million Research Grant
The quest to end malignant mesothelioma takes many forms: some researchers use surgery to eliminate tumors from the body, and others look to novel drugs to do the same. A pair of renowned physicians at Philadelphia’s Fox Chase Cancer Center are taking a different approach. They have received a three-year, $1.2 million grant to see
-
Asbestos Defendant Argues Lung Cancer Victim Was Employee
The vast majority of those diagnosed with malignant pleural mesothelioma and asbestos-related lung cancer were exposed to the carcinogenic material in their workplace. Because workers’ compensation rules prevent these victims from suing their employer, they often seek justice from others who negligently exposed them. In a recent case, an asbestos defendant unsuccessfully attempted to say
-
Combining Chemotherapy with Treatment that Starves Mesothelioma Cells Extends Survival
After twenty years of investigation, a researcher in the United Kingdom has confirmed that his discovery has created a breakthrough in mesothelioma survival. Professor Peter Szlosarek of Queen Mary University of London has just concluded a Phase III clinical trial that quadrupled patients’ survival at 36 months.
-
Asbestos Company Fails in Multiple Attempts at Being Dismissed from Lung Cancer Claims
Perkins Engines was named a defendant in two different asbestos cases: one filed by Winfield P. Frederick who was diagnosed with asbestos-related lung cancer, and one filed by lung cancer victim Kenneth Nankervis. The company filed motions for summary judgment, looking to the Supreme Court of New York County to grant their request to evade
-
Expert Witness Testimony Prompts Urgent Action from Mesothelioma Victim’s Family
The family of Roseanna Matherne is seeking justice on her behalf following her death from malignant peritoneal mesothelioma. Mrs. Matherne was diagnosed with the disease after years of exposure to asbestos that her husband carried home from his job at Avondale Shipyards. In preparing for litigation, the family noted alarming testimony from one of the
-
Woman’s Mesothelioma Blamed on Second-Hand Asbestos Carried Home on Husband’s Work Clothes
Statistically speaking, the vast majority of malignant mesothelioma victims are elderly men who’d worked in high-heat settings decades before their diagnosis. But an alarming number of those men’s wives are also afflicted by the disease, largely as a result of having been exposed to asbestos carried home on their husband’s work clothes. That is what
-
Successful Test of AI and Molecular Twin Platform May Lead to Greater Accuracy in Mesothelioma Prognosis
Results from a Cedars-Sinai Cancer Center study suggest that artificial intelligence and precision medicine may soon lead to greater accuracy in survival predictions for malignant pleural mesothelioma. The research, published in Nature Cancer, details how scientists were able to use the technology to identify biomarkers that were superior to the tests currently in use.
-
Hess to Pay $187 Million in Mesothelioma and Asbestos Settlement
A notice of settlement has been filed by oil and gas company Hess Corporation, ending years of litigation filed by mesothelioma and other asbestos-related disease victims on the island of St. Croix. The company’s payment relates to negligence claims against its bankrupt unit HONX, which operated a refinery on the island from 1965 to 1998.
-
Mesothelioma Victim’s Family Reaches Settlement with Prominent Aerospace Companies
Malignant mesothelioma deaths lead to grief and financial hardship. The painful loss of loved ones and insurmountable medical bills lead many families to file lawsuits against the companies that are responsible. While some do battle for years, others allow their mesothelioma attorneys to settle their claims out of court so they can be compensated for
-
Seaman Files Asbestos Claim Against Shipping Company
After years of working as a commercial fisherman on ships he’d been told were contaminated with asbestos, Riccardo Ciolino began experiencing symptoms that he feared signaled mesothelioma. His doctors diagnosed him with a different disease that is also caused by exposure to asbestos, and he filed a claim against his former employer. Facing accusations of
-
Mesothelioma Vaccine Given Fast Track Status by FDA
The U.S. Food and Drug Administration has given fast-track designation to a promising new cancer vaccine used with nivolumab (Opdivo) and ipilimumab (Yervoy) in treating unresectable malignant pleural mesothelioma. The approval follows a recently completed phase 2 clinical trial that offered promising results.
-
Navy Veteran Describes “Dirty Work” in Mesothelioma Claim
It is a tragic but true fact that America’s service branches made frequent use of asbestos for decades, and as a result, a significant portion of mesothelioma victims in the United States are veterans. Asbestos companies are frequently named in personal injury lawsuits seeking compensation for the harm that veterans have suffered. In a recent case,
-
First Patient Dosed in Phase 2 Clinical Study of Drug for Pleural Mesothelioma
Biotechnology company RS Oncology has announced the start of a new Phase 2 clinical study of its drug, RSO-021 for the treatment of malignant pleural mesothelioma and other thoracic malignancies, and the successful first dosing of a patient. The multicenter study based in the United Kingdom is evaluating the drug’s impact on patients suffering the
-
J&J’s Attorneys Question Ovarian Cancer Talc Victims’ Reliance on Mesothelioma Study
Johnson & Johnson is currently facing over 40,000 personal injury claims blaming its talc for cases of ovarian cancer and malignant pleural mesothelioma. At issue is whether the product causes these illnesses and whether the company was aware of its dangers. As multidistrict litigation exclusively filed by ovarian cancer victims is set to begin in
-
Novel Defense in Asbestos Lung Cancer Lawsuit Defeated
In 2019, Francesco Carboni died of asbestos-related lung cancer. His widow, Susan, blamed the asbestos he was exposed to as a result of his work as an auto mechanic for his exposure and blamed multiple companies. Included among them was a company operating as Alfa Romeo USA. After years of participating in the litigation, the
-
Welder’s Mesothelioma Blamed on Asbestos in Safety Gloves
Mario Caligiuri blames his mesothelioma diagnosis on the asbestos he was exposed to during his career as a welder. When filed a personal injury lawsuit against companies whose asbestos-contaminated products he used or was exposed to, he included Olympic Glove & Safety Co., Inc. whose gloves he wore in the 1970s. Olympic filed a motion
-
Colgate Palmolive’s Attempt to Dismiss Mesothelioma Claim Called “Substantively Defective”
Last October, Paula Corin filed a personal injury claim against forty-three different companies, blaming them for exposing her to the asbestos that caused her malignant pleural mesothelioma. Her suit was filed in the Los Angeles County Superior Court, and the day after she filed, Colgate-Palmolive removed the case to the U.S. District Court on the
-
Study Reveals Benefit of Combining Pembrolizumab with Chemotherapy for Pleural Mesothelioma
Immunotherapy treatment has become one of the greatest sources of optimism for patients with cancers of all types, including mesothelioma. A group of international researchers recently released the findings of their study investigating combining one immunotherapy drug, pembrolizumab, with the gold standard chemotherapy treatment for the rare asbestos-related disease and found that it significantly improved patients’
